शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSENorris Medicines Ltd· Commercial Services & SuppliesHighNeutral
Announced Fri, 14 Nov, 2025 · 18:38 IST

As per attachment.

Revenue growth above 20%Net loss reportedGoing-concern doubtDebt to equity above the thresholdResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.8%Reaction day
₹15.35
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-1.4% vs market
Trading & Distributors peers, median of 130sector-0.7%-0.1% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 0.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.8+0.6-1.4-0.7-0.1
Next day
+3.8-0.2+4.0-1.3+5.1
2d
-0.3-0.4+0.1-2.0+1.6
3d
+6.2-0.7+6.9-2.4+8.6
4d
+7.2-2.2+9.4-3.1+10.3
5d
+0.8-2.8+3.7-4.3+5.1
1w
-0.7-1.4+0.8-3.3+2.7
15d
-2.3-7.0+4.7-7.0+4.7
1m
+8.2-6.1+14.3-6.8+15.0
2m
-3.8-9.2+5.4-12.0+8.1
3m
-5.7-6.8+1.1-12.8+7.0
UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 130Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved un-audited financial results along with a clean (unqualified) Limited Review Report from statutory auditors Bahedia & Associates. Revenue from operations grew sharply: Q2 FY26 revenue was Rs. 200.04 lakhs vs Rs. 126.84 lakhs in Q2 FY25 (~58% growth), and H1 FY26 revenue rose to Rs. 345.70 lakhs vs Rs. 199.33 lakhs (~73% growth). However, losses deepened in parallel – Q2 loss widened to Rs. 71.82 lakhs (vs Rs. 36.11 lakhs) and H1 loss to Rs. 102.86 lakhs (vs Rs. 72.73 lakhs). The full-year FY25 loss stood at Rs. 123.75 lakhs. Cost of materials consumed spiked to Rs. 248.24 lakhs in Q2 (vs just Rs. 17.51 lakhs a year ago), indicating severe margin pressure despite top-line growth. The balance sheet shows a deeply negative net worth of Rs. -1,589.62 lakhs (negative other equity of Rs. -2,582.19 lakhs) with total borrowings of about Rs. 2,147 lakhs. Operating cash flow remained marginally positive at Rs. 34.69 lakhs for H1.

Likely market impact

Strong revenue growth is being completely offset by rising input costs and widening losses, with the company's equity fully eroded into the negative. This is a serious red flag for shareholders — the negative net worth and ongoing losses raise going-concern concerns and pose downside risk to the stock. Investors should look for clear signs of margin recovery or capital infusion before reassessing the outlook.